Q Therapeutics

Q Therapeutics is a private, clinical-stage biotech based in Salt Lake City, pioneering a novel glial cell replacement therapy for neurodegenerative and demyelinating diseases. The company's platform utilizes purified human glial progenitor cells (Q-Cells®) as an off-the-shelf, non-genetically manipulated therapeutic to address the underlying causes of CNS disorders. With an FDA-allowed IND for a Phase 1/2a trial in Transverse Myelitis and a broad potential pipeline including ALS and multiple sclerosis, Q Therapeutics is positioned to target significant unmet medical needs in neurology. The company is led by CEO Steve Borst and leverages a strong intellectual property portfolio of over 20 issued patents.

Human glial progenitor cell platform for allogeneic, off-the-shelf cell therapy. Cells are purified from brain tissue, non-genetically manipulated, and differentiate into astrocytes and oligodendrocytes to support and repair neurons in the CNS.

Q Therapeutics competes in the crowded and challenging field of neurology, facing large pharma and biotech firms developing small molecules, antibodies, and other cell/gene therapies. Its unique focus on glial cell replacement differentiates it, but it must prove clinical superiority or a unique mechanism in areas with growing competition, like ALS and MS.